Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 263

1.

Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.

Navarro J, Santos JR, Silva A, Burgos J, Falcó V, Ribera E, Imaz A, Curran A.

Pharmacotherapy. 2019 Feb 5. doi: 10.1002/phar.2227. [Epub ahead of print]

PMID:
30723941
2.

New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.

Ribera E.

AIDS Rev. 2018;20(4):179-186. doi: 10.24875/AIDSRev.M18000026.

PMID:
30548024
3.

Brief Report: Effectiveness of Trichloroacetic Acid vs. Electrocautery Ablation for the Treatment of Anal High-Grade Squamous Intraepithelial Lesion in HIV-Infected Patients.

Burgos J, Martin-Castillo M, Landolfi S, Dinares MC, Villar J, Navarro J, Ribera E, Falcó V, Curran A.

J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):612-616. doi: 10.1097/QAI.0000000000001847.

PMID:
30179983
4.

Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.

Perez-Molina JA, Pulido F, Di Giambenedetto S, Ribera E, Moreno S, Zamora J, Coscia C, Alejos B, Pitch J, Gatell JM, De Luca A, Arribas JR.

J Antimicrob Chemother. 2018 Nov 1;73(11):2927-2935. doi: 10.1093/jac/dky299.

PMID:
30085184
5.

Antiretroviral Therapy in Advanced HIV Disease: Which is the Best Regimen?

Burgos J, Ribera E, Falcó V.

AIDS Rev. 2018 Jan-Mar;20(1):3-13. Review.

PMID:
29369304
6.

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

Moltó J, Curran A, Miranda C, Challenger E, Santos JR, Ribera E, Khoo S, Valle M, Clotet B.

J Antimicrob Chemother. 2018 Mar 1;73(3):732-737. doi: 10.1093/jac/dkx459.

PMID:
29237008
7.

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group.

Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734.

PMID:
29020293
8.

Cardiac surgery in adults with high-surgical complexity CHD: results of a network collaborative programme.

Gilad V, Santoro F, Ribera E, Calevo MG, Cipriani A, Pasquè A, Chierchia SL.

Cardiol Young. 2018 Jan;28(1):101-107. doi: 10.1017/S1047951117001664. Epub 2017 Aug 29.

PMID:
28847320
9.

The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM.

Burgos J, Hernández-Losa J, Landolfi S, Guelar A, Dinares M, Villar J, Navarro J, Ribera E, Falcó V, Curran A.

AIDS. 2017 Oct 23;31(16):2227-2233. doi: 10.1097/QAD.0000000000001605.

PMID:
28723712
10.

A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.

Grau-Expósito J, Serra-Peinado C, Miguel L, Navarro J, Curran A, Burgos J, Ocaña I, Ribera E, Torrella A, Planas B, Badía R, Castellví J, Falcó V, Crespo M, Buzon MJ.

MBio. 2017 Jul 11;8(4). pii: e00876-17. doi: 10.1128/mBio.00876-17.

11.

Epidemiological trends of HIV-1 infection in blood donors from Catalonia, Spain (2005-2014).

Bes M, Piron M, Casamitjana N, Gregori J, Esteban JI, Ribera E, Quer J, Puig L, Sauleda S.

Transfusion. 2017 Sep;57(9):2164-2173. doi: 10.1111/trf.14195. Epub 2017 Jul 5.

PMID:
28681400
12.

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.

PLoS One. 2017 Feb 9;12(2):e0172184. doi: 10.1371/journal.pone.0172184. eCollection 2017.

13.

Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan.

Ribera E, Martínez-Sesmero JM, Sánchez-Rubio J, Rubio R, Pasquau J, Poveda JL, Pérez-Mitru A, Roldán C, Hernández-Novoa B.

Enferm Infecc Microbiol Clin. 2018 Mar;36(3):157-164. doi: 10.1016/j.eimc.2016.11.015. Epub 2017 Jan 20. English, Spanish.

PMID:
28109551
14.

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.

Saumoy M, Tiraboschi JM, Ordoñez-Llanos J, Ribera E, Domingo P, Mallolas J, Curto J, Gatell JM, Podzamczer D.

HIV Clin Trials. 2017 Mar;18(2):49-53. doi: 10.1080/15284336.2016.1275425. Epub 2017 Jan 12.

PMID:
28081673
15.

Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment.

Navarro J, Curran A, Burgos J, Torrella A, Ocaña I, Falcó V, Crespo M, Ribera E.

Antivir Ther. 2017;22(1):89-90. doi: 10.3851/IMP3075. Epub 2016 Aug 22.

PMID:
27546463
16.

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A; GESIDA-8314 Study Group.

PLoS One. 2016 Oct 11;11(10):e0164455. doi: 10.1371/journal.pone.0164455. eCollection 2016. Erratum in: PLoS One. 2017 Feb 9;12 (2):e0172184.

17.

Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.

Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, Martinez E, Ryan P, Górgolas M, Podzamczer D, Knobel H, Gutiérrez F, Ribera E.

J Antimicrob Chemother. 2016 Dec;71(12):3510-3514. Epub 2016 Sep 2.

PMID:
27591292
18.

Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.

Teira R, Vidal F, Muñoz-Sánchez P, Geijo P, Viciana P, Ribera E, Domingo P, Castaño M, Martínez E, Roca B, Puig T, Estrada V, Deig E, Galindo MJ, de la Fuente B, Lozano F, Montero M, Muñoz-Sanz A, Sanchez T, Terrón A, Romero-Palacios A, Lacalle JR, Garrido M, Suárez-Lozano I; VACH Study Group.

HIV Med. 2017 Mar;18(3):196-203. doi: 10.1111/hiv.12413. Epub 2016 Aug 1.

19.

Short-length ligamentum arteriosum as a cause of congenital narrowing of the left main stem bronchus.

Sacco O, Santoro F, Ribera E, Magnano GM, Rossi GA.

Pediatr Pulmonol. 2016 Dec;51(12):1356-1361. doi: 10.1002/ppul.23460. Epub 2016 Apr 29.

PMID:
27128381
20.

Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.

Crespo M, Navarro J, Martinez-Rebollar M, Podzamczer D, Domingo P, Mallolas J, Saumoy M, Mateo GM, Curran A, Gatell J, Ribera E.

HIV Clin Trials. 2016 May;17(3):89-95. doi: 10.1080/15284336.2016.1149929. Epub 2016 Mar 16.

PMID:
27125363

Supplemental Content

Loading ...
Support Center